Brokerages Set DaVita Inc. (NYSE:DVA) PT at $145.60

Shares of DaVita Inc. (NYSE:DVA) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $145.60.

DVA has been the subject of several research reports. TD Cowen reduced their price objective on DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research report on Monday, November 3rd. Truist Financial cut their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. UBS Group restated a “buy” rating on shares of DaVita in a research report on Monday, December 15th. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Barclays reduced their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research note on Thursday, October 30th.

DaVita Stock Performance

Shares of NYSE:DVA opened at $104.55 on Friday. The stock’s 50-day moving average is $117.18 and its 200-day moving average is $128.42. The company has a market cap of $7.38 billion, a P/E ratio of 10.77, a P/E/G ratio of 0.68 and a beta of 0.99. DaVita has a 52-week low of $104.24 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last announced its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. DaVita’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, equities analysts predict that DaVita will post 10.76 EPS for the current year.

Institutional Trading of DaVita

Institutional investors and hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. boosted its position in DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. MAI Capital Management raised its stake in shares of DaVita by 23.4% in the second quarter. MAI Capital Management now owns 438 shares of the company’s stock valued at $62,000 after acquiring an additional 83 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares in the last quarter. Teacher Retirement System of Texas grew its position in DaVita by 1.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 6,696 shares of the company’s stock worth $954,000 after acquiring an additional 94 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in DaVita by 34.9% during the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock valued at $59,000 after purchasing an additional 117 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.